ArticleMaedica2026
Evaluation of Health-Related Quality of Life in Patients Treated with Synbiotics: a Prospective Observational Study.
Article in Maedica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Abdominal bloating and gastrointestinal discomfort are common complaints that significantly impair patients' health-related quality of life (HRQoL). Probiotic and synbiotic formulations have been proposed as supportive therapies for improving gastrointestinal symptoms and patient-reported outcomes, yet real-world data on their impact on HRQoL remain limited. Our objective was to evaluate changes in physical and mental components of HRQoL in adult patients treated with a synbiotic formulation containing Saccharomyces boulardii SB01, Lactobacillus bulgaricus LB42, Lactobacillus rhamnosus LRa05 and fructooligosaccharides (FOS) in routine clinical practice. Materials and methods: This prospective monocentric observational study included 50 adult patients treated with a synbiotic formulation containing Saccharomyces boulardii SB01, Lactobacillus bulgaricus LB42, Lactobacillus rhamnosus LRa05 and FOS for 15 days. Health-related quality of life was assessed using the 12-item Short Form Health Survey (SF-12) at baseline and at 30-day follow-up. Changes in SF-12 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were analyzed using Wilcoxon signed-rank tests. Clinically meaningful improvement was defined using the minimal clinically important difference (MCID). Effect sizes were calculated and correlations between changes in PCS and MCS were assessed using Spearman's rho. Results: The PCS scores improved significantly from baseline to follow-up (mean change +4.42, p-value= 0.003). Clinically meaningful improvement in physical HRQoL was observed in 46% of participants. In contrast, MCS scores declined significantly over the same period (mean change -9.17, p-value < 0.001) and no participants achieved MCID for mental HRQoL. Changes in physical and mental HRQoL were not significantly correlated (p-value = 0.112). Conclusions: In routine clinical practice, treatment with the studied synbiotic formulation was associated with a statistically significant and clinically meaningful improvement in physical HRQoL, while mental HRQoL showed a significant decline over the short-term follow-up. These findings highlight divergent trajectories of physical and mental health outcomes and underscore the importance of multidimensional HRQoL assessment in patients with gastrointestinal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.